293780 — AptaBio Therapeutics Balance Sheet
0.000.00%
- KR₩202bn
- KR₩178bn
- KR₩3bn
Annual balance sheet for AptaBio Therapeutics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS/A | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 42,825 | 22,911 | 16,995 | 51,885 | 31,496 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 680 | 479 | 3,047 | 2,659 | 1,435 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 43,745 | 23,777 | 20,419 | 57,474 | 34,935 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 4,889 | 4,822 | 5,848 | 5,129 | 4,962 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 75,444 | 64,911 | 56,114 | 92,519 | 77,434 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 801 | 788 | 1,040 | 818 | 19,540 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 3,403 | 3,246 | 3,744 | 31,156 | 23,237 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 72,040 | 61,665 | 52,370 | 61,363 | 54,197 |
Total Liabilities & Shareholders' Equity | 75,444 | 64,911 | 56,114 | 92,519 | 77,434 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |